ClinicalTrials.gg
TerminatedNCT01131325MACS1148Updated May 20, 2021Results posted

Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations

A Phase 4 interventional study of nilotinib in CML, Philadelphia Chromosome Positive (Ph+) and Chronic Myelogenous Leukemia Chronic Phase(CML-CP) Patients With Low Imatinib Trough Levels, sponsored by Novartis Pharmaceuticals. Terminated at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-05-20.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
3
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing nilotinib in Leukemia, Myeloid, Chronic-Phase — 1 open to participants now, 2 under way, none of them phase 3. nilotinib · Leukemia, Myeloid, Chronic-Phase.

Enrollment
14th of 14
3 · median 69
Started
2010
the only one that year
Phase 4
2 of 14
none open now
Registered
6th of 14
by date
Lead sponsor
3 of 14
Novartis Pharmaceuticals

Among the 14 studies testing nilotinib in Leukemia, Myeloid, Chronic-Phase, this one is the 14th largest by enrollment, is the only one that started in 2010, is one of 2 in phase 4, and was the 6th registered.

Leukemia, Myeloid, Chronic-Phase

439 studies on the registry are indexed under Leukemia, Myeloid, Chronic-Phase; 27 are open to participants now.

Browse Leukemia, Myeloid, Chronic-Phase studies →

Open to participants now

1 of the 14 studies testing nilotinib in Leukemia, Myeloid, Chronic-Phase is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About nilotinib

nilotinib: first FDA approval 2007 (TASIGNA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Leukemia, Myeloid, Chronic-Phase studies recruiting now, 13 (65%) set no upper age limit and 5 (25%) stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing nilotinib in Leukemia, Myeloid, Chronic-Phase, or all of them as a file.
02

Study summary

This study is to determine the number of European Leukemia Network (ELN)guideline defined treatment failure events from time of study entry in CML-CP patients with low imatinib trough concentrations treated with nilotinib.

03

Conditions studied

  • CML
  • Philadelphia Chromosome Positive (Ph+)
  • Chronic Myelogenous Leukemia Chronic Phase(CML-CP) Patients With Low Imatinib Trough Levels

Keywords

  • Philadelphia chromosome positive
  • Ph+
  • chronic myelogenous leukemia chronic phase
  • CML-CP
  • low imatinib trough levels
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Cytogenetically confirmed Ph+ CML-CP Any prior dose of Imatinib
  • Imatinib 400 mg daily for ≥7 consecutive days prior to imatinib trough collection
  • Imatinib trough plasma concentration \<850 ng/mL

Exclusion criteria

Exclusion Criteria:

  • Prior documented failure events as defined by ELN guidelines:
  • Loss of CHR, CCyR, or clonal progression/Ph+
  • Less than CHR at 3 months after diagnosis
  • No CyR at 6 months after diagnosis
  • Less than PCyR at 12 months after diagnosis
  • Less than CCyR at 18 months after diagnosis
  • Prior accelerated phase or blast phase CML
  • Previously documented T315I mutation
  • Previous treatment for CML with any other tyrosine kinase inhibitor except for imatinib
  • Patients who had any other treatment for CML (transplant) except interferon +/- ara- C, imatinib, hydroxyurea and/or anagrelide
  • Impaired cardiac function
  • Patients receiving therapy with strong inhibitors of or medications that prolong the and cannot be either discontinued or switched to a different medication prior to starting study drug.
  • Any other that is or requires active intervention.
  • Major surgery within 4 weeks prior to Day 1 of study or who have not recovered from prior surgery
  • Treatment with other agents within 30 days of Day 1
  • Women who are pregnant, breast feeding, or of without a negative serum test at baseline. women must be amenorrhoeic for at least 12 months to be considered of non-childbearing potential. Women of childbearing potential must have a negative serum pregnancy test within 7 days of the first dose of nilotinib
  • Sexually active male and female patients taking nilotinib unwilling to use adequate throughout the trial and 3 months following discontinuation of study drug
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
3 participants (actual)

Study arms

  • Experimental
    Nilotinib

    Drug: nilotinib

Interventions

  • All patients will receive nilotinib 300mg bid po daily. Nilotinib dose is taken every 12 hours

    Also known as: AMN107, Tasigna

06

What researchers measure

Primary outcomes

  1. Number of Treatment Failure Events up to 2 Years

    Treatment failure events from time of study entry in Complete molecular response-Chronic phase (CML-CP) participants with low imatinib trough concentrations less than 850 nanogram per milliliter (\<850 ng/mL) treated with nilotinib as defined in European LeukemiaNet (ELN)-guideline.

    Time frame: up to 2 years

Secondary outcomes

  1. European LeukemiaNet (ELN)-Defined Optimal Responses

    Time frame: up to 2 years

  2. Loss of Complete Cytogenetic Response (CCyR), Major Molecular Response (MMR) and Complete Molecular Response (CMR) on Nilotinib

    Complete Cytogenetic Response (CCyR) is defined as 0% of Ph+ metaphases. A patient was counted as CCyR at 12 cycles if the patient met the CCyR criteria at the Cycle 12 Visit. Major molecular response is defined as values equal or below 0.1% on the International Scale. Complete Molecular Response is defined as a Bcr-Abl (a fusion of gene of Bcr and ABl genes) ratio ≤0.0032% on the International Scale Bcr = breakpoint cluster gene Abl = abelson proto-oncogene.

    Time frame: up to 2 years

  3. Duration of Complete Cytogenetic Response (CCyR), Major Molecular Response (MMR) and Complete Molecular Response (CMR)Achieved on Nilotinib

    Durations of major/complete cytogenetic response is defined as the time from the first documentation of the major/ complete response to the first documentation of the disease progression.

    Time frame: up to 2 years

  4. Event-free Survival (EFS), Progression-free Survival (PFS) and Overall Survival (OS) up to 2 Years

    Event-free survival was defined as the time from the date of randomization to the date of first occurrence of any of the following events on study treatment: loss of complete hematological response, confirmed loss of complete cytogenetic response (CCyR), confirmed loss of major molecular response (MMR), death from any cause during treatment, progression to the accelerated phase or blast crisis of chronic myelogenous leukemia (CML) per European Leukemia Network (ELN) criteria, whichever was earliest. Progressions free survival is defined as time between Day 1 cycle 1 and time to first documented disease progression or death. Disease progression will be determined as per response criteria. Overall survival time is defined as the time from the treatment start to the date of death due to any reason.

    Time frame: up to 2 years

  5. European LeukemiaNet (ELN)-Defined Suboptimal Events

    Time frame: up to 2 years

  6. Number of Participants Reported Adverse Events

    An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, or is an event of possible drug-induced liver injury.

    Time frame: Up to 2 years

07

Results

Posted May 20, 2021
Limitations and caveats
The study was terminated early due to slow enrollment.

Participant flow

The study was conducted at 3 centers in the United States.

Participant flow — Overall Study
MilestoneNilotinib
Started3
Completed0
Not completed3
Withdrew: Adverse event1
Withdrew: The participants discontinued the study as the study got terminated2

Outcome measures

PrimaryNumber of Treatment Failure Events up to 2 Years

Treatment failure events from time of study entry in Complete molecular response-Chronic phase (CML-CP) participants with low imatinib trough concentrations less than 850 nanogram per milliliter (\<850 ng/mL) treated with nilotinib as defined in European LeukemiaNet (ELN)-guideline.

Time frame:
up to 2 years

No measurements were reported for this outcome.

SecondaryEuropean LeukemiaNet (ELN)-Defined Optimal Responses
Time frame:
up to 2 years

No measurements were reported for this outcome.

SecondaryLoss of Complete Cytogenetic Response (CCyR), Major Molecular Response (MMR) and Complete Molecular Response (CMR) on Nilotinib

Complete Cytogenetic Response (CCyR) is defined as 0% of Ph+ metaphases. A patient was counted as CCyR at 12 cycles if the patient met the CCyR criteria at the Cycle 12 Visit. Major molecular response is defined as values equal or below 0.1% on the International Scale. Complete Molecular Response is defined as a Bcr-Abl (a fusion of gene of Bcr and ABl genes) ratio ≤0.0032% on the International Scale Bcr = breakpoint cluster gene Abl = abelson proto-oncogene.

Time frame:
up to 2 years

No measurements were reported for this outcome.

SecondaryDuration of Complete Cytogenetic Response (CCyR), Major Molecular Response (MMR) and Complete Molecular Response (CMR)Achieved on Nilotinib

Durations of major/complete cytogenetic response is defined as the time from the first documentation of the major/ complete response to the first documentation of the disease progression.

Time frame:
up to 2 years

No measurements were reported for this outcome.

SecondaryEvent-free Survival (EFS), Progression-free Survival (PFS) and Overall Survival (OS) up to 2 Years

Event-free survival was defined as the time from the date of randomization to the date of first occurrence of any of the following events on study treatment: loss of complete hematological response, confirmed loss of complete cytogenetic response (CCyR), confirmed loss of major molecular response (MMR), death from any cause during treatment, progression to the accelerated phase or blast crisis of chronic myelogenous leukemia (CML) per European Leukemia Network (ELN) criteria, whichever was earliest. Progressions free survival is defined as time between Day 1 cycle 1 and time to first documented disease progression or death. Disease progression will be determined as per response criteria. Overall survival time is defined as the time from the treatment start to the date of death due to any reason.

Time frame:
up to 2 years

No measurements were reported for this outcome.

SecondaryEuropean LeukemiaNet (ELN)-Defined Suboptimal Events
Time frame:
up to 2 years

No measurements were reported for this outcome.

SecondaryNumber of Participants Reported Adverse Events

An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, or is an event of possible drug-induced liver injury.

Time frame:
Up to 2 years
Reported as:
Count of participants · Participants
Number of Participants Reported Adverse Events
ParticipantsNilotinib
Number of Participants Reported Adverse Events2

Adverse events

Collected over up to 2 years. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nilotinib0/3 (0%)0/3 (0%)2/3 (66.7%)
Most frequent other events
Showing 10 of 11
Most frequent other events
EventNilotinib
Muscle cramps - legsMusculoskeletal and connective tissue disorders1/3
ThrombocytopeniaBlood and lymphatic system disorders1/3
NeutropeniaBlood and lymphatic system disorders1/3
NauseaGastrointestinal disorders1/3
VomitingGastrointestinal disorders1/3
FatigueGeneral disorders1/3
RashSkin and subcutaneous tissue disorders1/3
Pruritus GenitalSkin and subcutaneous tissue disorders1/3
Rhinitis allergicRespiratory, thoracic and mediastinal disorders1/3
Sore ThroatInfections and infestations1/3

Baseline characteristics

All enrolled participants.

Age, Categorical
Age, Categorical(Participants)Nilotinib
<=18 years0
Between 18 and 65 years3
>=65 years0
Sex: Female, Male
Sex: Female, Male(Participants)Nilotinib
Female0
Male3
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Nilotinib
Caucasian3
08

Study locations

3 sites
  • Comprehensive Cancer Centers of Nevada CCC of Nevada (1)
    Las Vegas, Nevada 89109, United States
  • Cancer Center of the High Plains
    Amarillo, Texas 79106, United States
  • Baylor Health Care System/Sammons Cancer Center Dept. of Sammons Cancer (2)
    Dallas, Texas 75246, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2010 to primary completion in May 2011, 6 months.

Results were first posted in May 2021, 10 years after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 25, 2010
First posted
May 26, 2010
StartActual
Oct 21, 2010
Primary completionActual
May 12, 2011
CompletionActual
May 12, 2011
Results first posted
May 20, 2021
Last update
May 20, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01131325
Responsible party
Sponsor
First posted
May 26, 2010
Start date
Oct 21, 2010
Primary completion
May 12, 2011
Completion
May 12, 2011
Results posted
May 20, 2021
Last update
May 20, 2021

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nilotinib

Start the discussion